Ctrl Worx Watch List › Company

Alzamend Neuro, Inc. (ALZN): material weakness open 2,008 days

By Russell Tomoum, Ctrl Worx™. Built from its own SEC filings. How the Clock works.

Alzamend Neuro, Inc. reported ineffective internal control over financial reporting because of a material weakness in 21 filings since Sep 13, 2021. It stated one or more material weaknesses in 1 more SEC filing that gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Jul 31, 2026.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #11259

Causes the company named

Accounting expertise and resources · 21ITGC: user access · 12ITGC: change management · 12Financial close and reporting · 8Complex or non-routine accounting · 4Not described · 1

Insufficient accounting department resources limit reviews of journal entries, reconciliations, and non-routine transaction accounting.

What the latest filing says

f our principal executive officer and principal financial officer has concluded that the Company’s internal control over financial reporting was not effective as of the end of the period covered by this Quarterly Report on Form 10-Q because the Company has not yet completed its remediation of the material weakness previously identified and disclosed in the Company’s Annual Report on Form 10-K for the year ended April 30, 2026, the end of its most recent fiscal year. 24 Specifically, management has identified the following material weakness: · We do not have sufficient resources in our accounting department, which restricts our ability to perform sufficient reviews and approval of manual journal entries posted to the general ledger and to consistently execute review procedures over general ledger account reconciliations, financial statement preparation and accounting for non-routine transactions. A material weakness is a control deficiency or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim fi [...]

From the controls section of the 10-Q filed Sep 10, 2026. Read the full filing on SEC EDGAR.

Company response: Alzamend Neuro, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

Follow ALZN for free

Get an email when Alzamend Neuro, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with Alzamend Neuro, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.